AAIC 2015

AAIC 2015 Coverage

Summary Score in Middle Age Predicts Dementia Status Later in Life

By

Stan Grossman

July 23, 2015

A five question screening tool focusing on middle-age educational and occupational attainment helps predict dementia risk.

AAIC 2015 Coverage

AVP-923 Reduces Agitation in Patients with Alzheimer’s Disease

By

Haymarket Media

July 22, 2015

Currently FDA-approved for treating pseudo bulbar affect, the drug also benefits agitation.

Reducing intracranial pressure after head injury

AAIC 2015 Coverage

Can Amyloid PET Scans Improve Dementia Outcomes?

By

Haymarket Media

July 22, 2015

The first randomized-controlled clinical trials are underway to assess if early access to amyloid imaging PET scan results can inform treatment decisions for mild cognitive impairment and dementia.

Growth Hormone May Help Social Impairments in Autism

AAIC 2015 Coverage

Biogen’s Aducanumab Offers Mixed Results in Alzheimer’s Progression

By

Jonathan Block

July 22, 2015

The big question now is what doses will Biogen examine in aducanumab phase 3 trials.

Non-memory Alzheimer's symptoms more likely in younger people

AAIC 2015 Coverage

Investigational Neurotransmitter May Enhance Treatment for Alzheimer’s Symptoms

By

Kathleen Tulley, Editorial Director

July 22, 2015

RVT-101 improved cognition and function when combined with donepezil in patients with mild to moderate Alzheimer’s disease.

AAIC 2015 Coverage

Caffeine May Help To Maintain Memory, Inhibit Cognitive Impairment

By

Jonathan Block

July 22, 2015

Greater intake of caffeine among healthy older adults was associated with better memory and executive functioning.

AAIC 2015 Coverage

Solanezumab Shows Modest Effect on Alzheimer’s Disease Progression

By

Kathleen Tulley, Editorial Director

July 22, 2015

Investigators identified a possible disease-modifying effect of solanezumab as an early treatment for Alzheimer’s disease, but the benefit in clinical practice remains unclear.